435 studies found for:    (human papillomavirus OR hpv) AND (woman OR women OR female)
Show Display Options
Rank Status Study
21 Completed Impact of an HPV Vaccine in HIV-Infected Young Women
Condition: HIV Infection
Intervention: Biological: HPV vaccine for strains -6, -11, -16, and -18
22 Active, not recruiting A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)
Condition: Human Papillomavirus Infection
Intervention: Biological: V503 (9-valent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) vaccine)
23 Enrolling by invitation Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
Condition: Human Papillomavirus
Interventions: Biological: HPV 16/18 vaccine, 0,5ml;   Biological: Placebo control, 0.5ml;   Biological: HPV 16/18 vaccine, 1.0ml;   Biological: Placebo control, 1.0ml
24 Completed
Has Results
Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Condition: Infections, Papillomavirus
Interventions: Biological: CervarixTM;   Biological: HPV investigational vaccine GSK568893A, different formulations
25 Active, not recruiting Vaginal Self-sampling and Human Papillomavirus Testing in Unscreened Women
Condition: Cancer Cervix
Interventions: Behavioral: Group 1 remove self sample kit at gp consulting room or perform pap smear;   Behavioral: Group 2 perform self sample at home or pap smear
26 Completed
Has Results
Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
Conditions: HIV Infections;   Sexually Transmitted Diseases
Intervention: Biological: Quadrivalent HPV vaccine
27 Completed
Has Results
Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)
Conditions: Genital Warts;   Anal Cancer;   Anal Intraepithelial Neoplasia
Intervention: Biological: 9vHPV Vaccine
28 Completed Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
29 Completed The Human Papillomavirus (HPV) Transmission Pilot Study
Condition: Human Papillomavirus Infection
30 Recruiting Video to Promote HPV Vaccination
Conditions: Vaccine Acceptance;   Social Acceptance;   Acceptance Processes;   Health Behavior;   Human Papillomavirus
Intervention: Other: Educational Video with Male or Female Narrator
31 Completed Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents
Condition: Infections, Papillomavirus
Interventions: Biological: GSK Biologicals' HPV Vaccine GSK580299;   Biological: Engerix-B™
32 Active, not recruiting HPV Testing for Cervical Cancer Screening Study
Condition: Cervical Cancer Screening
Intervention: Procedure: Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive
33 Completed
Has Results
Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Condition: Papillomavirus Vaccines
Intervention: Biological: Cervarix™ (HPV-16/18 L1 VLP AS04)
34 Completed
Has Results
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
Conditions: Inflammatory Bowel Disease;   Uterine Cervical Dysplasia
Intervention: Biological: Human Papillomavirus Vaccine
35 Enrolling by invitation Extended Follow-Up of Young Women in Costa Rica Who Received Vaccination Against Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
Conditions: Cervical Cancer;   Human Papillomavirus;   Anal Cancer;   Oral Cancer
36 Completed
Has Results
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Condition: HPV-16/18 Infections and Cervical Neoplasia
Intervention: Biological: Cervarix TM
37 Completed A Study to Examine the Human Papillomavirus Types Exposure in Women From Southern Africa and Brasil
Conditions: HIV;   HIV Infections
38 Completed
Has Results
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
Conditions: Cervical Cancer;   Nonneoplastic Condition;   Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine;   Genetic: DNA analysis;   Genetic: polymerase chain reaction;   Other: cytology specimen collection procedure;   Procedure: colposcopic biopsy
39 Completed
Has Results
Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine 580299 in Healthy Females 10 - 25 Years of Age.
Conditions: HPV-16/18 Infections;   Cervical Neoplasia
Interventions: Biological: CervarixTM;   Biological: Placebo vaccine (Al(OH)3)
40 Not yet recruiting Evaluation of an Mhealth Intervention to Increase Adherence to Triage of HPV+ Women
Condition: Patient Adherence
Intervention: Other: mHealth Intervention Group

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years